ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2026
An integrated extraction-free LAMP platform with colorimetric, real-time, and immunochromatographic strip detection for rapid male-specific DNA screening in forensic triage.
Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rapid identification of male-derived biological evidence enhances forensic casework efficiency, particularly in sexual assault investigations that require prioritization of male DNA for downstream short tandem repeat (STR) analysis. Here, we present an extraction-free direct loop-mediated isothermal amplification (LAMP) workflow targeting the Y-chromosomal sex-determining region Y (SRY) gene for male-specific DNA detection, with the autosomal human leukocyte antigen DRA (HLA-DRA) gene incorporated as a human-specific internal control. Three detection formats were systematically evaluated within a single extraction-free framework: colorimetric LAMP enabled visual SRY detection within 30 min at 65 °C; multiplex real-time LAMP simultaneously detected both SRY and HLA-DRA within 15 min, achieving limits of detection of 100 pg per reaction for male DNA and 10 pg per reaction for total human DNA; and an immunochromatographic strip (ICS)-based format provided instrument-free visual discrimination between male, female, and non-human samples through simultaneous dual-target readout on a single strip. To assess field applicability, five direct lysis reagents were evaluated for compatibility with each detection modality. Nuclease-free water preserved the pH conditions required for colorimetric detection, enabling reliable male DNA identification from whole blood diluted up to 1:25 and saliva diluted up to 1:5. NaOH-based lysis improved DNA release and amplification kinetics in real-time LAMP, enabling detection from blood diluted up to 1:125 and saliva diluted up to 1:625. A UDG/dUTP anti-contamination system was optimized for the ICS format to suppress carry-over-derived false-positive signals while maintaining robust visual band intensity-an essential requirement for reliable point-of-care interpretation. The optimized workflow was validated across multiple forensically relevant matrices including whole blood, saliva, swab-collected samples, and cigarette butt mock evidence, consistently discriminating male- from female-derived biological material. These results demonstrate that direct LAMP, when paired with appropriate lysis chemistry and detection modality, provides a rapid, sensitive, and operationally practical strategy for on-site male DNA screening and forensic evidence triage.
Indexed as
Identifiers
42690552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.